|
Oct 17
|
Hansa Biopharma Reports Third Quarter and Interim January - September 2024 Financial Results
|
|
Dec 7
|
Imlifidase demonstrated positive safety, tolerability, and early efficacy outcomes in 15-HMedIdeS-09 phase 2 trial in Guillain-Barré Syndrome (GBS)
|
|
Dec 5
|
Hansa Biopharma plans restructuring to strengthen long-term competitiveness and advance key deliverables
|